Lipid Profiles in Patients with Rheumatoid Arthritis: Mechanisms and the Impact of Treatment

Seminars in Arthritis and Rheumatism

Volumn 38, Issue 5, 2009, Pages 372-381

  Steiner, George ^a   Urowitz, Murray B ^b  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

cardiovascular risk; inflammation; lipids; rheumatoid arthritis; treatment

Indexed keywords

ADALIMUMAB; APOLIPOPROTEIN A1; ATLIZUMAB; ATORVASTATIN; C REACTIVE PROTEIN; CHLOROQUINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; EZETIMIBE; FATTY ACID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE; SIMVASTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADD ON THERAPY; ANKYLOSING SPONDYLITIS; ARTICLE; ATHEROSCLEROSIS; BODY FAT; BODY FAT DISTRIBUTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DYSLIPIDEMIA; EXERCISE; HIGH RISK POPULATION; HUMAN; HYPERINSULINEMIA; INFLAMMATION; INSULIN RESISTANCE; MEDLINE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RISK FACTOR; RISK REDUCTION;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; HUMANS; LIPIDS; RISK FACTORS; VASCULITIS;

EID: 62849084638     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2008.01.015     Document Type: Article

References (68)

1. Gonzalez-Gay M.A., Gonzalez-Juanatey C., and Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Sem Arthritis Rheum 35 (2005) 8-17
2. Li A.C., and Glass C.K. The macrophage foam cell as a target for therapeutic intervention. Nat Med 8 (2002) 1235-1242
3. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
4. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon III R.O., Criqui M., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
5. Assous N., Touze E., Meune C., Kahan A., and Allanore Y. Cardiovascular disease in rheumatoid arthritis: single-center hospital-based cohort study in France. Joint Bone Spine 74 (2007) 66-72
6. Solomon D.H., Goodson N.J., Katz J.N., Weinblatt M.E., Avorn J., Setoguchi S., et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 65 (2006) 1608-1612
7. Turesson C., Jarenros A., and Jacobsson L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheum Dis 63 (2004) 952-955
8. Goodson N., Marks J., Lunt M., and Symmons D. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis 64 (2005) 1595-1601
9. Warrington K.J., Kent P.D., Frye R.L., Lymp J.F., Kopecky S.L., Goronzy J.J., et al. Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study. Arthritis Res Ther 7 (2005) R984-R991
10. Maradit-Kremers H., Nicola P.J., Crowson C.S., Ballman K.V., and Gabriel S.E. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52 (2005) 722-732
11. del Rincon I., Williams K., Stern M., Freeman G., O'Leary D., and Escalante A. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 48 (2003) 1833-1840
12. Sattar N., McCarey D.W., Capell H., and McInnes I.B. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108 (2003) 2957-2963
13. NCEP. Third report of the National Cholesterol Education Program (NCEP) expert panel on: Detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). Executive Summary. NIH Publication no. 01-3670. May 2001.
14. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
15. Karvounaris S.A., Sidiropoulos P.I., Papadakis J.A., Spanakis E.K., Bertsias G.K., Kritikos H.D., et al. Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study. Ann Rheum Dis 66 (2007) 28-33
16. Dessein P.H., Joffe B.I., and Stanwix A.E. Subclinical hypothyroidism is associated with insulin resistance in rheumatoid arthritis. Thyroid 14 (2004) 443-446
17. Dessein P.H., Tobias M., and Veller M.G. Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol 33 (2006) 2425-2432
18. Dessein P.H., and Joffe B.I. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 54 (2006) 2765-2775
19. Doria A., Sherer Y., Meroni P.L., and Schoenfeld Y. Inflammation and accelerated atherosclerosis: basic mechanisms. Rheum Dis Clin North Am 31 (2005) 355-362
20. Yeh E.T.H. CRP as a mediator of disease. Circulation 109 (2004) 11-14
21. Kaplan M.J. Cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol 18 (2006) 289-297
22. Emery P., Gabay C., Kraan M., and Gomez-Reino J. Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. Rheumatol Int 27 (2007) 793-806
23. Dessein P., Joffe B., and Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 7 (2005) R634-R643
24. Allanore Y., Kahan A., Sellam J., Ekindjian O.G., and Borderie D. Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin Chim Acta 365 (2006) 143-148
25. Seriolo B., Paolino S., Sulli A., Fasciolo D., and Cutolo M. Effects of anti-TNF-a treatment on lipid profile in patients with active rheumatoid arthritis. Ann NY Acad Sci 1069 (2006) 414-419
26. Papanicolaou D.A., Wilder R.L., Manolagas S.C., and Chrousos G.P. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 128 (1998) 127-137
27. Fernandez-Real J.M., Broch M., Vendrell J., Richart C., and Ricart W. Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab 85 (2000) 1334-1339
28. Yudkin J., Kumari M., Humphries S., and Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis 148 (2000) 209-214
29. Gomaraschi M., Basilico N., Sisto F., Taramelli D., Eligini S., Colli S., et al. High-density lipoproteins attenuate interleukin-6 production in endothelial cells exposed to pro-inflammatory stimuli. Biochim Biophys Acta 1736 (2005) 136-143
30. Popa C., Netea M.G., Radstake T., Van der Meer J.W.M., Stalenhoef A.F.H., van Riel P.L.C., et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 64 (2005) 303-305
31. Feingold K.R., Soued M., Staprans I., Gavin L.A., Donahue M.E., Huang B., et al. Effect of tumor necrosis factor (TNF) on lipid metabolism in the diabetic rat: evidence that inhibition of adipose tissue lipoprotein lipase activity is not required for TNF-induced hyperlipidemia. J Clin Invest 83 (1989) 1116-1121
32. Ofei F., Hurel S., Newkirk J., Sopwith M., and Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45 (1996) 881-885
33. Choi H.K., and Seeger J.D. Lipid profiles among US elderly with untreated rheumatoid arthritis-the Third National Health and Nutrition Examination Survey. J Rheumatol 32 (2005) 2311-2316
34. Dursunoglu D., Evrengul H., Polat B., Tanriverdi H., Cobankara V., Kaftan A., et al. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int 25 (2005) 241-245
35. Georgiadis A.N., Papavasiliou E.C., Lourida E.S., Alamanos Y., Kostara C., Tselepis A.D., et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment-a prospective, controlled study. Arthritis Res Ther 8 (2006) R82
36. Park Y.B., Lee S.K., Lee W.K., Suh C.H., Lee C.W., Lee C.H., et al. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 26 (1999) 1701-1704
37. Asanuma Y., Kawai S., Aoshima H., Kaburaki J., and Mizushima Y. Serum lipoprotein(a) and apolipoprotein(a) phenotypes in patients with rheumatoid arthritis. Arthritis Rheum 42 (1999) 443-447
38. Frolkis J.P. Should one routinely screen for lipoprotein(a)?. Cleve Clin J Med 66 (1999) 465-468
39. Dessein P.H., Stanwix A.E., and Joffe B.I. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 4 (2002) R5
40. van Halm V.P., van Denderen J.C., Peters M.J., Twisk J.W., van der Paardt M., van der Horst-Bruinsma I.E., et al. Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. Ann Rheum Dis 65 (2006) 1473-1477
41. Boers M., Nurmohamed M.T., Doelman C.J.A., Lard L.R., Verhoeven A.C., Voskuyl A.E., et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 62 (2003) 842-845
42. Cauza E., Cauza K., Hanusch-Enserer U., Etemad M., Dunky A., and Kostner K. Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien Klin Wochenschr 114 (2002) 1004-1007
43. Dessein P.H., Joffe B.I., and Stanwix A.E. Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study. Arthritis Res 4 (2002) R12
44. Dessein P.H., Joffe B.I., Stanwix A.E., Christian B.F., and Veller M. Glucocorticoids and insulin sensitivity in rheumatoid arthritis. J Rheumatol 31 (2004) 867-874
45. Irace C., Mancuso G., Fiaschi E., Madia A., Sesti G., and Gnasso A. Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis 177 (2004) 113-118
46. Kiortsis D.N., Mavridis A.K., Filippatos T.D., Vasakos S., Nikas S.N., and Drosos A.A. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 33 (2006) 921-923
47. Kyriazis N.C., Brianas L., and Koumaditis A. Lipid profile in patients with active rheumatoid arthritis under infliximab therapy. Ann Rheum Dis 64 Suppl 3 (2005) Poster 553
48. Maini R.N., Taylor P.C., Szechinski J., Pavelka K., Broll J., Balint G., et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54 (2006) 2817-2829
49. Park Y.B., Choi H.K., Kim M.Y., Lee W.K., Song J., Kim D.K., et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med 113 (2002) 188-193
50. Peters M.J., Vis M., van Halm V.P., Wolbink G.J., Voskuyl A.E., Lems W.F., et al. Changes in lipid profile during infliximab treatment and corticosteroid therapy in rheumatoid arthritis. Ann Rheum Dis 66 (2007) 958-961
51. Tam L.S., Tomlinson B., Chu T.T., Li T.K., and Li E.K. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 26 (2007) 1495-1498
52. Vis M., Nurmohamed M.T., Wolbink G., Voskuyl A.E., De Koning M., van de Stadt R.J., et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 32 (2005) 252-255
53. Alkaabi J.K., Ho M., Levison R., Pullar T., and Belch J.J. Rheumatoid arthritis and macrovascular disease. Rheumatology (Oxford) 42 (2003) 292-297
54. Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol 49 (2007) 2003-2009
55. Undas A., Celinska-Lowenhoff M., Domagala T.B., Iwaniec T., Dropinski J., Lowenhoff T., et al. Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. Thromb Haemost 94 (2005) 193-199
56. Coban E., and Sari R. The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidemic obese patients. Endocr Res 30 (2004) 343-349
57. Muhlestein J.B., May H.T., Jensen J.R., Horne B.D., Lanman R.B., Lavasani F., et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol 48 (2006) 396-401
58. Okopien B., Krysiak R., and Herman Z.S. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab 91 (2006) 1770-1778
59. Fischetti F., Carretta R., Borotto G., Durigutto P., Bulla R., Meroni P.L., et al. Fluvastatin treatment inhibits leucocyte adhesion and extravasation in models of complement-mediated acute inflammation. Clin Exp Immunol 135 (2004) 186-193
60. Haruna Y., Morita Y., Yada T., Satoh M., Fox D.A., and Kashihara N. Fluvastatin reverses endothelial dysfunction and increased vascular oxidative stress in rat adjuvant-induced arthritis. Arthritis Rheum 56 (2007) 1827-1835
61. Leung B.P., Sattar N., Crilly A., Prach M., McCarey D.W., Payne H., et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 170 (2003) 1524-1530
62. ten Cate R., Nibbering P.H., and Bredius R.G. Therapy-refractory systemic juvenile idiopathic arthritis successfully treated with statins. Rheumatology (Oxford) 43 (2004) 934-935
63. McCarey D.W., McInnes I.B., Madhok R., Hampson R., Scherbakov O., Ford I., et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363 (2004) 2015-2021
64. Maki-Petaja K.M., Booth A.D., Hall F.C., Wallace S.M., Brown J., McEniery C.M., et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 50 (2007) 852-858
65. Okamoto H., and Kamatani N. Successful treatment with fenofibrate, a peroxisome proliferator activated receptor alpha ligand, for a patient with rheumatoid arthritis. Ann Rheum Dis 63 (2004) 1002-1003
66. Moon J.Y., Kwon H.M., Kwon S.W., Yoon S.J., Kim J.S., Lee S.J., et al. Lipoprotein(a) and LDL particle size are related to the severity of coronary artery disease. Cardiology 108 (2007) 282-289
67. Packard C.J. Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Curr Opin Lipidol 17 (2006) 412-417
68. Klareskog L., and Hamsten A. Statins in rheumatoid arthritis-two birds with one stone?. Lancet 363 (2004) 2011-2012